Karyopharm Therapeutics, Inc.

( )
KPTI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen Inc.
CELGCelgene Corporation
GILDGilead Sciences, Inc.
BIIBBiogen Inc.
NKTRNektar Therapeutics
REGNRegeneron Pharmaceuticals, Inc.
VRTXVertex Pharmaceuticals Incorporated
ALXNAlexion Pharmaceuticals, Inc.
ILMNIllumina, Inc.
AAgilent Technologies, Inc.
EXASExact Sciences Corporation
INCYIncyte Corporation
BLUEBluebird Bio, Inc.
SRPTSarepta Therapeutics, Inc.
BMRNBioMarin Pharmaceutical Inc.

Company Profile

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.